PE20030390A1 - Composicion farmaceutica que comprende mometasona furoato y formoterol fumarato - Google Patents

Composicion farmaceutica que comprende mometasona furoato y formoterol fumarato

Info

Publication number
PE20030390A1
PE20030390A1 PE2002000820A PE2002000820A PE20030390A1 PE 20030390 A1 PE20030390 A1 PE 20030390A1 PE 2002000820 A PE2002000820 A PE 2002000820A PE 2002000820 A PE2002000820 A PE 2002000820A PE 20030390 A1 PE20030390 A1 PE 20030390A1
Authority
PE
Peru
Prior art keywords
mometasone furoate
box
formoterol fumarate
pharmaceutical composition
composition including
Prior art date
Application number
PE2002000820A
Other languages
English (en)
Spanish (es)
Inventor
Stefan A Sharpe
John L Hart
Joel A Sequeira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20030390A1 publication Critical patent/PE20030390A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2002000820A 2001-08-28 2002-08-27 Composicion farmaceutica que comprende mometasona furoato y formoterol fumarato PE20030390A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28

Publications (1)

Publication Number Publication Date
PE20030390A1 true PE20030390A1 (es) 2003-04-24

Family

ID=23224164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000820A PE20030390A1 (es) 2001-08-28 2002-08-27 Composicion farmaceutica que comprende mometasona furoato y formoterol fumarato

Country Status (26)

Country Link
US (3) US20030114428A1 (enExample)
EP (3) EP1420759B1 (enExample)
JP (3) JP2005502675A (enExample)
KR (1) KR100970531B1 (enExample)
CN (2) CN1649568B (enExample)
AR (1) AR036358A1 (enExample)
AT (2) ATE430555T1 (enExample)
AU (1) AU2002313828B2 (enExample)
BR (1) BR0212089A (enExample)
CA (1) CA2457926A1 (enExample)
CO (1) CO5560551A2 (enExample)
CY (2) CY1109212T1 (enExample)
DE (2) DE60239648D1 (enExample)
DK (2) DK1420759T3 (enExample)
ES (3) ES2389480T3 (enExample)
HU (1) HUP0401514A3 (enExample)
MX (1) MXPA04001875A (enExample)
NO (1) NO20041277L (enExample)
NZ (1) NZ530987A (enExample)
PE (1) PE20030390A1 (enExample)
PL (1) PL209640B1 (enExample)
PT (2) PT1420759E (enExample)
SI (2) SI1420759T1 (enExample)
TW (1) TWI324934B (enExample)
WO (1) WO2003020253A2 (enExample)
ZA (1) ZA200401419B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
ATE375142T1 (de) * 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
CA2495689A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
WO2004020289A1 (en) * 2002-08-27 2004-03-11 Schering Corporation Process for producing metered dose inhaler formulations
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP2201936B1 (en) * 2004-01-21 2013-06-19 Merck Sharp & Dohme Corp. Method of treating acute rhinosinusitis
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
WO2006105401A2 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
EP1981545A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
EP2117504A1 (en) * 2007-02-09 2009-11-18 Schering Corporation Stable pharmaceutical drug aerosols
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
MX2010007569A (es) * 2008-01-10 2011-03-21 Schering Corp Star Productos farmaceuticos para inhalacion, sistemas y usos.
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
AU2010253770B9 (en) * 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
MX2012005961A (es) 2009-11-25 2012-06-14 Boehringer Ingelheim Int Nebulizador.
KR101464053B1 (ko) * 2009-12-07 2014-11-20 랩터 세라퓨틱스 인크. 4-메틸피라졸 배합물
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
PH12012501666A1 (en) 2010-02-22 2012-11-05 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate, and a process to make it
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
CA2850084C (en) 2011-10-11 2020-07-07 Chiesi Farmaceutici S.P.A. Crystalline microparticles of a beta-agonist coated with a fatty acid
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
BR122022010094B1 (pt) 2014-05-07 2023-10-03 Boehringer Ingelheim International Gmbh Dispositivo indicador e recipiente
MX383195B (es) 2014-05-07 2025-03-13 Boehringer Ingelheim Int Recipiente, nebulizador y uso.
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
WO2016004103A1 (en) 2014-06-30 2016-01-07 Proveris Scientific Company Sampling apparatus for determining the amount and uniformity of a delivered dose of drug related methods
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3701940B1 (en) 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
EP3426329A4 (en) 2016-03-09 2019-11-13 Proveris Scientific Corporation METHOD FOR MEASURING THE UNITABILITY OF THE DOSE CONTENT OF INHALATION AND NOSING DEVICES
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
US20210338626A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN116583316A (zh) 2020-10-15 2023-08-11 普罗沃锐斯科学有限公司 用于吸入器测试的系统和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
ES2200771T3 (es) * 1991-06-10 2004-03-16 Schering Corporation Formulaciones en aerosol no clorofluorocarbonadas.
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
EP0927037B1 (en) * 1996-08-29 2001-07-11 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
EP1133301A1 (en) * 1998-11-26 2001-09-19 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
ES2220724T3 (es) * 2000-01-20 2004-12-16 Basilea Pharmaceutica Ag Composiciones de peptidos ciclicos administrables por via nasal.
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
DE60232251D1 (de) 2009-06-18
EP2092935B1 (en) 2011-03-30
HUP0401514A2 (hu) 2004-12-28
JP5170789B2 (ja) 2013-03-27
PT2092935E (pt) 2011-05-31
MXPA04001875A (es) 2004-06-15
EP1420759A2 (en) 2004-05-26
NO20041277L (no) 2004-03-26
ES2361805T3 (es) 2011-06-22
CY1111726T1 (el) 2015-10-07
JP2005502675A (ja) 2005-01-27
EP2092935A1 (en) 2009-08-26
US20100143269A1 (en) 2010-06-10
PL368897A1 (en) 2005-04-04
TWI324934B (en) 2010-05-21
BR0212089A (pt) 2004-08-03
CN101856362A (zh) 2010-10-13
CN1649568B (zh) 2010-10-27
EP1420759B1 (en) 2009-05-06
ES2389480T3 (es) 2012-10-26
CN1649568A (zh) 2005-08-03
EP2319494A1 (en) 2011-05-11
DE60239648D1 (de) 2011-05-12
ZA200401419B (en) 2005-01-26
KR20040031002A (ko) 2004-04-09
HK1060972A1 (en) 2004-09-03
EP2319494B1 (en) 2012-06-13
ATE430555T1 (de) 2009-05-15
PL209640B1 (pl) 2011-09-30
AU2002313828B2 (en) 2005-09-08
CA2457926A1 (en) 2003-03-13
DK1420759T3 (da) 2009-08-03
DK2092935T3 (da) 2011-07-18
HUP0401514A3 (en) 2012-08-28
JP2009185075A (ja) 2009-08-20
JP2010138184A (ja) 2010-06-24
ATE503461T1 (de) 2011-04-15
CO5560551A2 (es) 2005-09-30
AR036358A1 (es) 2004-09-01
PT1420759E (pt) 2009-06-30
KR100970531B1 (ko) 2010-07-16
SI2092935T1 (sl) 2011-07-29
ES2325316T3 (es) 2009-09-01
HK1128428A1 (en) 2009-10-30
HK1151987A1 (en) 2012-02-17
US20030114428A1 (en) 2003-06-19
US20050147565A1 (en) 2005-07-07
CY1109212T1 (el) 2014-07-02
WO2003020253A3 (en) 2003-05-22
WO2003020253A2 (en) 2003-03-13
SI1420759T1 (sl) 2009-10-31
NZ530987A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
CO5560551A2 (es) Composiciones farmaceuticas para el tratamiento del asma
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
BR9916865A (pt) Composição farmacêutica em aerossol contendohfa 227 e hfa 134a
PE20140101A1 (es) Formulacion para inhalacion que comprende aclidinio
AR018891A1 (es) Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol
GB2029441A (en) Powder aerosol composition
CA2519523A1 (en) Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
NZ526564A (en) Metered dose inhaler for salmeterol xinafoate
IS2563B (is) Ný blanda til innöndunar með lausþéttni sem er frá 0,28 til 0,38 g/ml, sem inniheldur búdesóníð
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
MX2021009845A (es) Minimizacion de la aglomeracion de material de revestimiento de particula de medicamento durante el almacenaje para estabilizar los tiempos de desintegracion de productos farmaceuticos.
CO4900027A1 (es) Formulaciones en aerosol de furoato de mometasona sin cloro- fluorocarburos .
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
DE60318727D1 (de) Verfahren zur herstellung von dosierinhalatorformulierungen
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
TR200101928T2 (tr) Geliştirilmiş kararlılığa sahip bileşimler
AR040894A1 (es) Metodos de incorporacion de un agente leudante quimico encapsulado en ingredientes de masa y composicion asi preparada
DE60120630D1 (de) Pharmazeutische Zusammensetzung enthaltend Xanthangummi
US3024165A (en) Effervescent acetyl-salicylic acid tablet
JPS62273912A (ja) 人体塗布用エアゾ−ル剤
JPS5964688A (ja) エアゾ−ル組成物
JPS63249566A (ja) 泡沫状芳香剤エアゾ−ル組成物
CH627075A5 (en) Inhalation composition comprising a dispersion or suspension of a medicament to be inhaled

Legal Events

Date Code Title Description
FC Refusal